|
|
Article: Sarah Cannon Research Institute Sponsors Large-Scale Breast Cancer Trial.
- Article from:
- Business Wire
- Article date:
- December 9, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
1,800 patients will join 5-year TITAN trial for cancer drug ixabepilone
NASHVILLE, Tenn. -- The Sarah Cannon Research Institute will enroll 1,800 breast cancer patients for its TITAN study, a clinical research trial investigating the role of ixabepilone (Ixempra) in the treatment of early breast cancer.
Chemotherapy immediately following initial surgery (adjuvant chemotherapy) is an important part of breast cancer treatment and has been proven to decrease the risk of cancer recurrence.
Ixabepilone recently received FDA approval for treatment of advanced breast cancer and is one of the most active drugs against this disease. However, ixabepilone ...